<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03106740</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000179</org_study_id>
    <secondary_id>1R01NS095937-01A1</secondary_id>
    <nct_id>NCT03106740</nct_id>
  </id_info>
  <brief_title>Evaluating the Role of Neuroinflammation in Low Back Pain</brief_title>
  <acronym>IGNITE</acronym>
  <official_title>Imaging Glia-mediated NeuroInflammation and Treatment Efficacy (the IGNITE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marco Loggia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research, the study team will use brain imaging to evaluate the presence of
      neuroinflammation in the brains and spinal cords of patients with low back pain. The efficacy
      of minocycline use for low back pain treatment will also be evaluated by observing whether
      short-term minocycline administration will reduce neuroinflammation and low back pain
      symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this research study is to evaluate whether the central nervous systems of those
      with low back pain are different from those of healthy, pain-free individuals. Specifically,
      the researchers will test whether &quot;glial cells&quot; (the immune cells of the brain and spinal
      cord) are more active in patients with low back pain than in healthy volunteers. The
      investigators' previous study showed that patients with chronic low back pain demonstrated
      elevations in brain levels of the 18kDa translocator protein (TSPO), a marker of glial
      activation.

      To test this hypothesis, the study team will image the brains and spinal cords of patients
      suffering from low back pain using integrated magnetic resonance- positron emission
      tomography (MR-PET), and a radiotracer called [11C]PBR28, which tracks levels of glial
      activation.

      The efficacy of minocycline as a treatment for chronic low back pain will also be evaluated.
      A recent study demonstrated a statistically significant reduction in pain in those with
      lumbar radiculopathy after treatment with minocycline, leading the investigators of this
      study to believe that minocycline may have potential efficacy in treating other back pain
      populations.

      The study team will observe whether a short course of minocycline hydrochloride may reduce
      glial activation along with self-reported low back pain symptoms. To this end, patients will
      be evaluated clinically and/or re-scanned after completing a 2-week trial of minocycline,
      placebo (a sugar pill), or no treatment.

      This study will be enrolling individuals who have been suffering from sub-acute (short-term)
      and chronic low back pain.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in brain PET signal</measure>
    <time_frame>2 weeks</time_frame>
    <description>The investigators will test for the presence of a significant treatment*time interaction in the brain [11C]PBR28 signal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in spinal PET signal</measure>
    <time_frame>2 weeks</time_frame>
    <description>The investigators will test for the presence of a significant treatment*time interaction in the spinal [11C]PBR28 signal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pain outcomes as measured by self report on a 0-100 numerical pain rating scale</measure>
    <time_frame>2 weeks</time_frame>
    <description>The investigators will test for the presence of a significant treatment*time interaction in pain outcomes on a self reported numerical (0-100) pain rating scale.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Low Back Pain</condition>
  <condition>Back Pain With Radiation</condition>
  <condition>Back Pain Without Radiation</condition>
  <condition>Back Pain Lower Back Chronic</condition>
  <condition>Back Ache</condition>
  <condition>Pain, Chronic</condition>
  <arm_group>
    <arm_group_label>Natural History Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging before a waiting period, without treatment, followed by a behavioral pain assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minocycline Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 2-week trial of Minocycline Hydrochloride, 100mg capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after 2 weeks of treatment with a placebo capsule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline Hydrochloride 100mg Capsule</intervention_name>
    <description>Minocycline 100mg will be administered by mouth daily for 2 weeks</description>
    <arm_group_label>Minocycline Arm</arm_group_label>
    <other_name>Minocin</other_name>
    <other_name>Solodyn</other_name>
    <other_name>Dynacin</other_name>
    <other_name>Myrac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnetic Resonance-Positron Emission Tomography Imaging</intervention_name>
    <description>Up to 15 millicuries of [11C]PBR28 will be administered to each subject at each imaging visit, for a total of 2 imaging visits.</description>
    <arm_group_label>Natural History Arm</arm_group_label>
    <arm_group_label>Minocycline Arm</arm_group_label>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Capsule</intervention_name>
    <description>1 Placebo Capsule (compounded with lactose powder) will be administered by mouth daily for 2 weeks</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the ability to give written informed consent

          -  fluency in English

          -  on a stable pain treatment

          -  Chronic or sub-acute low back pain

        Exclusion Criteria:

          -  no interventional pain procedures during drug trial

          -  contraindications to MRI and PET scanning (including presence of a cardiac pacemaker
             or pacemaker wires, metallic particles in the body, vascular clips in the head or
             previous neurosurgery, prosthetic heart valves, claustrophobia)

          -  pregnancy or breast feeding

          -  any use of recreational drugs in the past 6 months

          -  allergy to minocycline or other tetracyclines, or taking medications known to interact
             with minocycline

          -  any other contraindications to minocycline administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco L Loggia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco L Loggia, PhD</last_name>
    <phone>617-643-7267</phone>
    <email>marco@nmr.mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Courtney A Bergan</last_name>
    <phone>617-643-6748</phone>
    <email>cbergan@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Loggia, PhD</last_name>
      <phone>617-643-7267</phone>
      <email>marco.loggia@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Loggia ML, Chonde DB, Akeju O, Arabasz G, Catana C, Edwards RR, Hill E, Hsu S, Izquierdo-Garcia D, Ji RR, Riley M, Wasan AD, ZÃ¼rcher NR, Albrecht DS, Vangel MG, Rosen BR, Napadow V, Hooker JM. Evidence for brain glial activation in chronic pain patients. Brain. 2015 Mar;138(Pt 3):604-15. doi: 10.1093/brain/awu377. Epub 2015 Jan 12.</citation>
    <PMID>25582579</PMID>
  </reference>
  <reference>
    <citation>Vanelderen P, Van Zundert J, Kozicz T, Puylaert M, De Vooght P, Mestrum R, Heylen R, Roubos E, Vissers K. Effect of minocycline on lumbar radicular neuropathic pain: a randomized, placebo-controlled, double-blind clinical trial with amitriptyline as a comparator. Anesthesiology. 2015 Feb;122(2):399-406. doi: 10.1097/ALN.0000000000000508.</citation>
    <PMID>25373391</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2017</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Marco Loggia</investigator_full_name>
    <investigator_title>Assistant Professor of Radiology, Research Staff</investigator_title>
  </responsible_party>
  <keyword>Microglia</keyword>
  <keyword>Minocycline</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Pain</keyword>
  <keyword>Astrocytes</keyword>
  <keyword>Glia</keyword>
  <keyword>Human</keyword>
  <keyword>Back Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

